Chien, Y.-H., Benjamin, E., Schoser, B., Kishnani, P., Mozaffar, T., Díaz-Manera, J., … Sileno, A. (2022). Immunogenicity of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease (LOPD): A phase III, randomized study (PROPEL). In Molecular Genetics and Metabolism (Vol. 135, pp. S30–S30). Elsevier BV. https://doi.org/10.1016/j.ymgme.2021.11.062

Chien, Yin-Hsiu, Elfrida Benjamin, Benedikt Schoser, Priya Kishnani, Tahseen Mozaffar, Jordi Díaz-Manera, Franklin Johnson, et al. “Immunogenicity of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease (LOPD): A phase III, randomized study (PROPEL).” In Molecular Genetics and Metabolism, 135:S30–S30. Elsevier BV, 2022. https://doi.org/10.1016/j.ymgme.2021.11.062.

Chien Y-H, Benjamin E, Schoser B, Kishnani P, Mozaffar T, Díaz-Manera J, et al. Immunogenicity of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease (LOPD): A phase III, randomized study (PROPEL). In: Molecular Genetics and Metabolism. Elsevier BV; 2022. p. S30–S30.

Chien, Yin-Hsiu, et al. “Immunogenicity of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease (LOPD): A phase III, randomized study (PROPEL).” Molecular Genetics and Metabolism, vol. 135, no. 2, Elsevier BV, 2022, pp. S30–S30. Crossref, doi:10.1016/j.ymgme.2021.11.062.

Chien Y-H, Benjamin E, Schoser B, Kishnani P, Mozaffar T, Díaz-Manera J, Johnson F, Das SS, Nair A, Williams H, Anderson E, Mondick JT, Sileno A. Immunogenicity of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease (LOPD): A phase III, randomized study (PROPEL). Molecular Genetics and Metabolism. Elsevier BV; 2022. p. S30–S30.